Hallucinations in Parkinson's disease: A follow‐up study
Identifieur interne : 001357 ( Istex/Corpus ); précédent : 001356; suivant : 001358Hallucinations in Parkinson's disease: A follow‐up study
Auteurs : Anne Doé De Maindreville ; Gilles Fénelon ; Florence MahieuxSource :
- Movement Disorders [ 0885-3185 ] ; 2005-02.
English descriptors
Abstract
To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (P = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20263
Links to Exploration step
ISTEX:46ADE8D52A0517D714C606F0AF89F8F927E0D764Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hallucinations in Parkinson's disease: A follow‐up study</title><author><name sortKey="Doe De Maindreville, Anne" sort="Doe De Maindreville, Anne" uniqKey="Doe De Maindreville A" first="Anne" last="Doé De Maindreville">Anne Doé De Maindreville</name><affiliation><mods:affiliation>Service de neurologie, Hôpital Maison Blanche, Reims, France</mods:affiliation></affiliation></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name><affiliation><mods:affiliation>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</mods:affiliation></affiliation></author><author><name sortKey="Mahieux, Florence" sort="Mahieux, Florence" uniqKey="Mahieux F" first="Florence" last="Mahieux">Florence Mahieux</name><affiliation><mods:affiliation>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:46ADE8D52A0517D714C606F0AF89F8F927E0D764</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20263</idno><idno type="url">https://api.istex.fr/document/46ADE8D52A0517D714C606F0AF89F8F927E0D764/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001357</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Hallucinations in Parkinson's disease: A follow‐up study</title><author><name sortKey="Doe De Maindreville, Anne" sort="Doe De Maindreville, Anne" uniqKey="Doe De Maindreville A" first="Anne" last="Doé De Maindreville">Anne Doé De Maindreville</name><affiliation><mods:affiliation>Service de neurologie, Hôpital Maison Blanche, Reims, France</mods:affiliation></affiliation></author><author><name sortKey="Fenelon, Gilles" sort="Fenelon, Gilles" uniqKey="Fenelon G" first="Gilles" last="Fénelon">Gilles Fénelon</name><affiliation><mods:affiliation>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</mods:affiliation></affiliation></author><author><name sortKey="Mahieux, Florence" sort="Mahieux, Florence" uniqKey="Mahieux F" first="Florence" last="Mahieux">Florence Mahieux</name><affiliation><mods:affiliation>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-02">2005-02</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="212">212</biblScope><biblScope unit="page" to="217">217</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">46ADE8D52A0517D714C606F0AF89F8F927E0D764</idno><idno type="DOI">10.1002/mds.20263</idno><idno type="ArticleID">MDS20263</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>hallucinations</term><term>ocular disease</term><term>sleep disorders</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (P = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anne Doé de Maindreville MD</name><affiliations><json:string>Service de neurologie, Hôpital Maison Blanche, Reims, France</json:string></affiliations></json:item><json:item><name>Gilles Fénelon MD, PhD</name><affiliations><json:string>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</json:string></affiliations></json:item><json:item><name>Florence Mahieux MD, PhD</name><affiliations><json:string>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>hallucinations</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sleep disorders</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ocular disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (P = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>6.333</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1730</abstractCharCount><pdfWordCount>3369</pdfWordCount><pdfCharCount>22283</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>247</abstractWordCount></qualityIndicators><title>Hallucinations in Parkinson's disease: A follow‐up study</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>5</total><last>217</last><first>212</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20263</json:string></doi><id>46ADE8D52A0517D714C606F0AF89F8F927E0D764</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/46ADE8D52A0517D714C606F0AF89F8F927E0D764/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/46ADE8D52A0517D714C606F0AF89F8F927E0D764/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/46ADE8D52A0517D714C606F0AF89F8F927E0D764/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Hallucinations in Parkinson's disease: A follow‐up study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Hallucinations in Parkinson's disease: A follow‐up study</title><author><persName><forename type="first">Anne</forename><surname>Doé de Maindreville</surname><roleName type="degree">MD</roleName></persName><affiliation>Service de neurologie, Hôpital Maison Blanche, Reims, France</affiliation></author><author><persName><forename type="first">Gilles</forename><surname>Fénelon</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Service de neurologie, Hôpital Henri Mondor, 94010‐Créteil cedex, France</p></note><affiliation>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</affiliation></author><author><persName><forename type="first">Florence</forename><surname>Mahieux</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-02"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="212">212</biblScope><biblScope unit="page" to="217">217</biblScope></imprint></monogr><idno type="istex">46ADE8D52A0517D714C606F0AF89F8F927E0D764</idno><idno type="DOI">10.1002/mds.20263</idno><idno type="ArticleID">MDS20263</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (P = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>hallucinations</term></item><item><term>sleep disorders</term></item><item><term>ocular disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-10-10">Received</change><change when="2004-05-17">Registration</change><change when="2005-02">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/46ADE8D52A0517D714C606F0AF89F8F927E0D764/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v20:2</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2005-02">February 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20263</doi><idGroup><id type="unit" value="MDS20263"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2003-10-10"></event><event type="manuscriptRevised" date="2004-05-08"></event><event type="manuscriptAccepted" date="2004-05-17"></event><event type="publishedOnlineEarlyUnpaginated" date="2004-08-31"></event><event type="firstOnline" date="2004-08-31"></event><event type="publishedOnlineFinalForm" date="2005-02-24"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">212</numbering><numbering type="pageLast">217</numbering></numberingGroup><correspondenceTo>Service de neurologie, Hôpital Henri Mondor, 94010‐Créteil cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20263.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="3198"></count></countGroup><titleGroup><title type="main" xml:lang="en">Hallucinations in Parkinson's disease: A follow‐up study</title><title type="short" xml:lang="en">Hallucinations in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anne</givenNames><familyName>Doé de Maindreville</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" corresponding="yes"><personName><givenNames>Gilles</givenNames><familyName>Fénelon</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email normalForm="gilles.fenelon@hmn.ap-hop-paris.fr">gilles.fenelon@hmn.ap‐hop‐paris.fr</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Florence</givenNames><familyName>Mahieux</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Service de neurologie, Hôpital Maison Blanche, Reims, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">hallucinations</keyword><keyword xml:id="kwd3">sleep disorders</keyword><keyword xml:id="kwd4">ocular disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (<i>P</i> = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Hallucinations in Parkinson's disease: A follow‐up study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Hallucinations in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Hallucinations in Parkinson's disease: A follow‐up study</title></titleInfo><name type="personal"><namePart type="given">Anne</namePart><namePart type="family">Doé de Maindreville</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service de neurologie, Hôpital Maison Blanche, Reims, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gilles</namePart><namePart type="family">Fénelon</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Service de neurologie, Hôpital Henri Mondor (AP‐HP), Créteil, France</affiliation><description>Correspondence: Service de neurologie, Hôpital Henri Mondor, 94010‐Créteil cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Florence</namePart><namePart type="family">Mahieux</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>CEGAP, Hôpital Charles Foix (AP‐HP), Ivry sur Seine, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-02</dateIssued><dateCaptured encoding="w3cdtf">2003-10-10</dateCaptured><dateValid encoding="w3cdtf">2004-05-17</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">16</extent><extent unit="words">3198</extent></physicalDescription><abstract lang="en">To study prevalence of hallucinations in patients with Parkinson's disease (PD) during a 1‐year period, and identify factors predictive of the onset of hallucinations in patients who were hallucination‐free at baseline, 141 unselected outpatients with PD were evaluated prospectively for a set of demographic, clinical, and therapeutic variables and the presence of hallucinations during the previous 3 months. Patient groups were compared with nonparametric tests, and logistic regression was applied to significant data. Follow‐up data were available for 127 patients. The hallucination prevalence rates (%) at the first and second evaluation were, respectively, 41.7 and 49.6 for hallucinations of all types (NS), 29.1 and 40.2 for minor hallucinations (i.e., presence or passage hallucinations, and illusions) (P = 0.02), 22.8 and 21.2 for formed visual hallucinations (NS), and 8.7 and 8.7 for auditory hallucinations (NS). Hallucinations rarely started or ceased during the study. The most labile forms were minor hallucinations, which developed in 20% of patients and ceased in 9%. During follow‐up, 15% of patients started to hallucinate. Three factors, all present at the first evaluation, independently predicted the onset of hallucinations in patients previously free of hallucinations at baseline (odds ratio; 95% confidence interval): severe sleep disturbances (14.3; 2.5–80.9), ocular disorders (9.1; 1.6–52.0), and a high axial motor score (5.7; 1.2–27.4). Hallucinations have a chronic course in most parkinsonian patients. Factors predicting the onset of hallucinations point to a role of extranigral brainstem involvement and a nonspecific, facilitating role of ocular disorders. © 2004 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>hallucinations</topic><topic>sleep disorders</topic><topic>ocular disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>212</start><end>217</end><total>5</total></extent></part></relatedItem><identifier type="istex">46ADE8D52A0517D714C606F0AF89F8F927E0D764</identifier><identifier type="DOI">10.1002/mds.20263</identifier><identifier type="ArticleID">MDS20263</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001357 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001357 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:46ADE8D52A0517D714C606F0AF89F8F927E0D764
|texte= Hallucinations in Parkinson's disease: A follow‐up study
}}
| This area was generated with Dilib version V0.6.23. |  |